1. GPCR/G Protein
  2. Leukotriene Receptor

Leukotriene Receptor

Leukotriene Receptor (cys-LTs) are a family of potent bioactive lipids that act through two structurally divergent G protein-coupled receptors, termed the CysLT1 and CysLT2 receptors. The cysteinyl leukotrienes LTC4, LTD4, and LTE4 are important mediators of human bronchial asthma. Leukotriene Receptor is a member of the superfamily of G protein-coupled receptors and uses a phosphatidylinositol-calcium second messenger system. Activation of CysLT1 by LTD4 results in contraction and proliferation of smooth muscle, oedema, eosinophil migration and damage to the mucus layer in the lung. Leukotriene receptor antagonists, called LTRAs for short, are a class of oral medication that is non-steroidal. They may also be referred to as anti-inflammatory bronchoconstriction preventors. LTRAs work by blocking a chemical reaction that can lead to inflammation in the airways.

Leukotriene Receptor Related Products (25):

Cat. No. Product Name Effect Purity
  • HY-19989A
    MK-571 sodium salt Antagonist 99.24%
    MK-571 sodium salt is a potent, selective, orally active leukotriene receptor antagonist, which inhibits [3H] LTD4 binding in guinea pig lung with a Ki of 0.22±0.15 nM and [3H]LTD4 binding in human lung with a Ki of 2.1±1.8 nM.
  • HY-13315
    Montelukast sodium Antagonist 99.82%
    Montelukast sodium is a potent, selective CysLT1 receptor antagonist.
  • HY-17492
    Zafirlukast Antagonist 99.10%
    Zafirlukast is a potent orally active leukotriene D4 (LTD4) receptor antagonist.
  • HY-B0290
    Pranlukast Antagonist >98.0%
    Pranlukast is a highly potent, selective and competitive antagonist of peptide leukotrienes. Pranlukast inhibits [3H]LTE4, [3H]LTD4, and [3H]LTC4 bindings to lung membranes with Kis of 0.63±0.11, 0.99±0.19, and 5640±680 nM, respectively.
  • HY-B0290A
    Pranlukast hemihydrate 99.89%
    Pranlukast hemihydrate is a highly potent, selective and competitive antagonist of peptide leukotrienes. Pranlukast inhibits [3H]LTE4, [3H]LTD4, and [3H]LTC4 bindings to lung membranes with Kis of 0.63±0.11, 0.99±0.19, and 5640±680 nM, respectively.
  • HY-19193
    CP-105696 Antagonist
    CP-105696 is a potent and selective Leukotriene B4 Receptor antagonist, with an IC50 of 8.42 nM.
  • HY-16344
    Nedocromil sodium Inhibitor
    Nedocromil sodium suppresses the action or formation of multiple mediators, including histamine, leukotriene C4 (LTC4), and prostaglandin D2 (PGD2).
  • HY-101944
    Iralukast
    Iralukast is a cysteinyl-leukotriene antagonist (CysLT) with a pKi of 7.8 for CysLT1.
  • HY-13448
    Nedocromil Inhibitor
    Nedocromil suppresses the action or formation of multiple mediators, including histamine, leukotriene C4 (LTC4), and prostaglandin D2 (PGD2).
  • HY-101946
    AS-35 Antagonist
    AS-35 is an orally effective, potent and selective antagonist of leukotrienes, antagonizes LTC4-, LTD4 and LTE4-induced contractions of the ileum with IC50 values of 8 nM, 4 nM and 3 nM, respectively, and has antiallergic activities.
  • HY-100173
    DW-1350 Antagonist
    DW-1350 is a LTB4 receptor antagonist.
  • HY-101438A
    Darbufelone mesylate Inhibitor
    Darbufelone mesylate is a dual inhibitor of cellular PGF and LTB4 production. Darbufelone potently inhibits PGHS-2 (IC50 = 0.19 μM) but is much less potent with PGHS-1 (IC50= 20 μM).
  • HY-100316
    CP-96486 Antagonist
    CP-96486 is a potent and orally active leukotriene D4 (LTD4)/platelet activating factor (PAF) receptor antagonist with Kis of 20 and 24 nM, respectively.
  • HY-U00027
    Quinotolast sodium Inhibitor
    Quinotolast sodium in the concentration range of 1-100 μg/mL inhibits histamine, LTC4 and PGD2 release in a concentration-dependent manner.
  • HY-101676
    RG-12525 Antagonist
    RG-12525 is a a specific, competitive and orally effective antagonist of the peptidoleukotrienes, LTC4, LTD4 and LTE4, inhibiting LTC4-, LTD4- and LTE4-inducd guinea pig parenchymal strips contractions, with IC50s of 2.6 nM, 2.5 nM and 7 nM, respectively; RG-12525 is also a peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist with IC50 of appr 60 nM and a potent inhibitor of CYP3A4, with a Ki value of 0.5 µM.
  • HY-101686
    LM-1484 Antagonist
    LM-1484 is an antagonist of CysLT1 receptor and displays a higher affinity for 3H-LTC4 sites.
  • HY-14938
    KCA 757 Antagonist
    KCA 757 is a sulfidopeptide leukotriene receptor antagonist, an orally bioavailable anti-inflammatory agent and used for the treatment of asthma.
  • HY-U00072
    RS-601 Antagonist
    RS-601 is a novel leukotriene D4 (LTD4)/thromboxane A2 (TxA2) dual receptor antagonist, with antiasthmatic activities.
  • HY-U00359
    LTD4 antagonist 1 Antagonist
    LTD4 antagonist 1 is a potent, orally active antagonist of leukotriene D4 (LTD4) with a Ki of 0.57 nM.
  • HY-U00263
    LY210073 Antagonist
    LY210073 is a Leukotriene B4 (LTB4) receptor antagonist with an IC50 of 6.2 nM.